Aviragen Therapeutics Inc Share Price Nasdaq
Stocks
US0906941002
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 26/06 | Vaxart Publishes Presentation to Shareholders | CI |
| 25/06 | Vaxart Provides Update to Barda Funding Award for Covid-19 Oral Pill Vaccine Trial | CI |
| Market Cap | 15Cr 13Cr 12Cr 11Cr 21Cr 1.38TCr 21Cr 141.48Cr 55Cr 681.11Cr 55Cr 54Cr 2.37TCr | P/E 2026 * |
2.09x | P/E 2027 * | -0.62x |
|---|---|---|---|---|---|
| Enterprise Value | 15Cr 13Cr 12Cr 11Cr 21Cr 1.38TCr 21Cr 141.48Cr 55Cr 681.11Cr 55Cr 54Cr 2.37TCr | EV / Sales 2026 * |
0.41x | EV / Sales 2027 * | - |
| Free-Float |
98.36% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Aviragen Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Steven Lo
CEO | Chief Executive Officer | 60 | 18/03/2024 |
Sean Tucker
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/03/2024 |
Jeroen Grasman
DFI | Director of Finance/CFO | - | 19/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
David Wheadon
BRD | Director/Board Member | 68 | 21/04/2021 |
William Watson
BRD | Director/Board Member | 76 | 04/08/2022 |
Elaine Heron
BRD | Director/Board Member | 79 | 01/04/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.31% | -0.20% | +72.71% | +128.31% | 5.58TCr | |
| -1.32% | +17.12% | +79.02% | +99.82% | 5.57TCr | |
| -1.28% | +2.68% | -12.60% | -13.79% | 2.38TCr | |
| +1.79% | +4.38% | +5.94% | +405.31% | 2.27TCr | |
| -1.93% | +11.11% | +34.89% | -7.86% | 1.85TCr | |
| +4.45% | +5.06% | +36.50% | -30.43% | 1.61TCr | |
| +0.24% | +5.98% | +23.45% | +184.72% | 1.36TCr | |
| +0.14% | +9.60% | +33.31% | - | 1.3TCr | |
| +1.83% | +4.58% | +77.42% | +132.45% | 1.22TCr | |
| Average | +0.80% | +6.10% | +38.96% | +112.32% | 2.57TCr | |
| Weighted average by Cap. | +0.80% | +5.21% | +48.48% | +114.84% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 36Cr 31Cr 29Cr 27Cr 51Cr 3.37TCr 51Cr 344.94Cr 133.91Cr 1.66TCr 133.71Cr 130.73Cr 5.78TCr | - |
| Net income | 12Cr 10Cr 9.37Cr 8.74Cr 16Cr 1.1TCr 17Cr 112.43Cr 44Cr 541.23Cr 44Cr 43Cr 1.89TCr | -28Cr -25Cr -23Cr -21Cr -40Cr -2.69TCr -41Cr -275.25Cr -106.86Cr -1.33TCr -106.7Cr -104.32Cr -4.62TCr |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
